On Thursday, Shares of Pfizer Inc. (NYSE:PFE), gained 1.37% to $31.84.
Shares of Pfizer (NYSE:PFE) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the stock, Analyst Ratings.Net reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $40.13.
Pfizer declared that it has accomplished the acquisition of GlaxoSmithKline’s quadrivalent meningococcal ACWY vaccines Nimenrix and Mencevax.
“The addition of Nimenrix and Mencevax assists us to fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide,” said Susan Silbermann, president and general manager, Pfizer Vaccines. “These vaccines add high-quality and complementary vaccines to our existing portfolio, allowing us to reach a broader global population.”
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a single-dose meningococcal ACWY-TT (tetanus toxoid) conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious disease that can lead to disability and death. It is indicated for all age groups above one year of age. Launched three years ago, Nimenrix is presently registered and approved for sale in 63 countries across the European Economic Area (EEA 30), Canada, Australia and Emerging Markets, with registrations under review in another 17 countries across Africa, Asia, Eastern Europe and the Middle East.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a single-dose meningococcal ACWY unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers in countries where the disease is endemic or highly epidemic. Mencevax is indicated for use across all age groups from 2 years of age, and is presently registered and approved in 78 countries across Africa, Asia, Australia, Europe, Latin America, Middle East and New Zealand.
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, counting inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, in addition to products for oncology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
